InfuSystem (INFU) Competitors

InfuSystem (NYSE:INFU) and AxoGen (NASDAQ:AXGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, community ranking, valuation, analyst recommendations and dividends.

Does the media favor INFU or AXGN?

In the previous week, AxoGen had 2 more articles in the media than InfuSystem. MarketBeat recorded 3 mentions for AxoGen and 1 mentions for InfuSystem. AxoGen's average media sentiment score of -0.16 beat InfuSystem's score of -1.00 indicating that AxoGen is being referred to more favorably in the news media.

Company	Overall Sentiment
InfuSystem	Negative
AxoGen	Neutral

Which has more volatility & risk, INFU or AXGN?

InfuSystem has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Comparatively, AxoGen has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500.

Do insiders & institutionals have more ownership in INFU or AXGN?

71.1% of InfuSystem shares are owned by institutional investors. Comparatively, 80.3% of AxoGen shares are owned by institutional investors. 11.4% of InfuSystem shares are owned by insiders. Comparatively, 2.8% of AxoGen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Do analysts rate INFU or AXGN?

InfuSystem presently has a consensus target price of $13.00, suggesting a potential upside of 113.46%. AxoGen has a consensus target price of $22.20, suggesting a potential upside of 118.29%. Given AxoGen's higher possible upside, analysts plainly believe AxoGen is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InfuSystem	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	4.00
AxoGen	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has preferable valuation & earnings, INFU or AXGN?

InfuSystem has higher earnings, but lower revenue than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InfuSystem	$137.58M	0.93	$870K	$0.14	43.50
AxoGen	$194.52M	2.38	-$21.72M	-$0.15	-67.80

Does the MarketBeat Community prefer INFU or AXGN?

AxoGen received 447 more outperform votes than InfuSystem when rated by MarketBeat users. However, 100.00% of users gave InfuSystem an outperform vote while only 72.93% of users gave AxoGen an outperform vote.

Company	Underperform	Outperform
InfuSystem	Outperform Votes 11 100.00%	Underperform Votes No Votes
AxoGen	Outperform Votes 458 72.93%	Underperform Votes 170 27.07%

Is INFU or AXGN more profitable?

InfuSystem has a net margin of 1.12% compared to AxoGen's net margin of -7.91%. InfuSystem's return on equity of 2.78% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InfuSystem	1.12%	2.78%	1.41%
AxoGen	-7.91%	-14.91%	-7.49%

Summary

InfuSystem beats AxoGen on 11 of the 19 factors compared between the two stocks.